<DOC>
	<DOCNO>NCT02070939</DOCNO>
	<brief_summary>This single multiple ascend dose study first evaluation PF-0626414 , Selective Androgen Receptor Modulator human . The goal ass safety , tolerability , pharmacokinetics pharmacodynamics healthy western Japanese male subject .</brief_summary>
	<brief_title>Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male age 21 50 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Additional inclusion criterion subject enrol Japanese cohort : Japanese subject four Japanese grandparent born Japan . Serum total testosterone level &lt; 270 &gt; 1070 ng/dL Serum Prostate Specific Antigen ( PSA ) level &gt; 4 ng/mL . Hematocrit &gt; 48 % . eGFR &gt; 150 ml/min/1.73m2 .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Randomized</keyword>
	<keyword>Double Blind</keyword>
	<keyword>Placebo-Controlled</keyword>
	<keyword>Single Multiple Dose Escalation</keyword>
	<keyword>Safety Tolerability</keyword>
	<keyword>PK</keyword>
	<keyword>PD</keyword>
	<keyword>PF-06460414</keyword>
</DOC>